- Saia Inc (NASDAQ:SAIA) reported second-quarter revenue growth of 36.6% year-over-year to $571.3 million, beating the consensus of $546.21 million.
- EPS improved to $2.34 from $1.07 in 2Q20, beating consensus of $2.00.
- The operating income increased by 132.4Y/Y to $82.9 million, and the margin expanded by 600 bps to 14.5%.
- The company reported an Operating ratio of 85.5% compared to 91.5% in 2Q20.
- Saia generated cash from operating activities year-to-date of $140.14 million, compared to $148.23 million a year ago.
- LTL shipments per workday increased 15.3%, tonnage per workday increased 23.1%, and revenue per hundredweight increased 10.5%. LTL revenue per shipment rose by 17.9% Y/Y to $277.24.
- Total debt was $61.0 million at June 30, 2021, and inclusive of the cash-on-hand, net debt to total capital was 0.8%.
- Net capital investments were $100.0 million in the first half of 2021.
- Saia said Shipper demand remains strong early in the third quarter. It anticipates net capital expenditures of $275 million in 2021.
- Price Action: SAIA shares are up 7.67% at $220.41 during the market session on the last check Thursday.
Reported Late Tuesday March 14, Jounce Therapeutics Confirms Receipt Of Unsolicited Proposal From Concentra Biosciences To Acquire 100% Of The Co. For $1.80/Share Subject To Diligence And Availability Of At Least $130M Of Cash And Equivalents At Closin…
The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer
